1. Scrip
  2. >>Therapy Areas

Delayed Reaction: BioMarin Rises On Pegvaliase Data

 
• By Mandy Jackson

BioMarin Pharmaceutical Inc. has bounced back from a stock price slump that occurred after it reported that pegvaliase, the company's second therapy to treat phenylketonuria (PKU), met the primary endpoint in a Phase III clinical trial, but failed to meet a key secondary endpoint.

BioMarin Pharmaceutical Inc. has bounced back from a stock price slump that occurred after it reported that pegvaliase, the company's second therapy to treat phenylketonuria (PKU), met the primary endpoint in a Phase III clinical trial, but failed to meet a key secondary endpoint.

BioMarin fell 3.4% on March 21, but jumped 6.7% to close at $83.43 per share on March 22 after investors...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By Joseph Haas

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By Kevin Grogan

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Obesity Beyond GLP-1s: Amylins – The Next Frontier

 
• By Aakash Babu

In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.